LabOS — the agentic operating system for distributed biology. Orchestrating multiomics computation, partner wet labs, and Apollo Hospitals' clinical biobank into closed-loop discovery for India and APAC.
The autonomous lab revolution is no longer theoretical — it has achieved commercial takeoff in 2026. Ginkgo Bioworks launched Ginkgo Cloud Lab in March 2026, running 36,000 experimental conditions in a closed-loop GPT-5-driven workflow with a 40% cost reduction over prior state-of-the-art. Recursion has aggregated over 50 petabytes of phenomics, transcriptomics, and proteomics data with millions of cell experiments per week. Isomorphic Labs raised $600M. Automata raised $45M (Series C, Feb 2026) with a Danaher partnership for modular lab automation. The race is on.
But the entire innovation axis runs through Boston, London, Salt Lake City, and London. India and APAC are invisible in this map — despite holding the world's most diverse patient populations, the largest untapped biological datasets, and the deepest cost arbitrage for R&D. That is the opening.
India is the world's 3rd largest clinical trial destination, produces 20% of global generic medicines, has 665 FDA-approved plants, and 1.4 billion people with unique genomic diversity — yet there is no indigenous platform bridging multiomics AI with autonomous wet-lab validation at scale.
The fundamental insight driving this venture is that biology's rate-limiting step has always been experimental data generation — not ideas. Autonomous labs eliminate this bottleneck by closing the Design-Build-Test-Learn (DBTL) loop at machine speed. But building the robots themselves is not the moat. The moat is in three things: the experimental graph (the typed, provenance-signed record of how every datapoint was produced), proprietary clinical data (Apollo Hospitals biobank), and an agent mesh that turns natural-language hypotheses into auditable wet-lab execution across heterogeneous partners.
LabOS is the agentic operating system for distributed biology — a multi-agent mesh that orchestrates multiomics computation, partner wet labs, and Apollo Hospitals' clinical biobank into closed-loop discovery. We do not own robots; we own the experimental graph and the India-tuned models running on top of it.
Multi-modal model integrating WGS/WES, scRNA-seq, spatial omics, proteomics, metabolomics, epigenomics. Generates hypotheses and ranks targets. Frontier-model wrappers in Year 1; fine-tuned, India-cohort-trained bio model on sovereign cloud by Year 2 (see Future-Proofing section).
A five-agent mesh (Hypothesis → Design → Execution → QC/Validator → Learning) that translates a goal into a typed experiment graph, routes nodes to the cheapest qualified partner (Syngene, Aragen, MedGenome, Ginkgo Cloud Lab, FAL Pods), captures provenance-signed results, and feeds the loop. LIMS-native: ingests from and writes to STARLIMS, LabWare, Benchling, LabVantage. No robots owned. The experimental graph is the moat.
Regulatory-grade packaging for CDSCO (India), TGA (AUS), PMDA (Japan), FDA/EMA bridging studies. Biomarker panels, IVD companion-diagnostic dossiers, Phase 4 pharmacovigilance signal packages. India-specific disease area specialization.
Anchor data partnership with Apollo — pan-India EHR, longitudinal clinical phenotyping, consented biospecimens. The India Biomarker Atlas is constructed on top of this substrate. See dedicated Apollo Partnership section.
The Strategic Blueprint is structured as five thematic pages. Pick whichever angle is most useful right now.
Why now, the five-agent mesh, LIMS-native integration, and the fine-tuning roadmap to sovereign India-tuned models.
Pan-India clinical substrate. Why this is the #1 pre-seed milestone and the competitive moat analysis.
Two costed flagship programs: IVD Companion Diagnostics and Phase 4 Pharmacovigilance. Offerings stack and customer segments.
Build-vs-partner, three-phase go-to-market, North Star metric & KPIs, and the agentic-lab risk plan.
APAC wet-lab operations hub, MiRXES partnership thesis, and the India↔Singapore corridor architecture.